The Association of PTPN22 R620W Polymorphism Is Stronger with Late-Onset AChR-Myasthenia Gravis in Turkey

A functional single nucleotide polymorphism (SNP) of the PTPN22 gene encoding a protein tyrosine phosphatase has been associated with autoimmune disorders including myasthenia gravis (MG). As the PTPN22 R620W polymorphism has a wide variation of allele frequencies among different populations, this polymorphism was investigated in MG in Turkey. An emphasis is put on MG subgroups according to autoantibody (Abs) production and presence of thymoma. DNA samples from 416 patients with clinically diagnosed generalized MG (231 with Abs to acetylcholine receptor, AChR-MG), 53 with Abs to muscle-specific kinase (MuSK-MG), 55 patients with no detectable Abs (SN-MG), 77 patients with thymoma (TAMG) and 293 healthy controls (HC) were genotyped for the SNP (PTPN22 R620W, C1858T, rs2476601). The PTPN22 T allele was increased in AChR-MG patients (odds ratio [OR]: 2.5, 95%CI: 1.2–5.1). The association was stronger in late disease-onset AChR (LOMG, OR: 3.1, 95%CI: 1.2–8.2). MuSK-MG, SN-MG and TAMG groups did not carry the variant allele more frequently than the HC. In contrast to findings in other autoimmune diseases, the distribution of the PTPN22 polymorphism in this population provides a susceptibility marker for AChR-MG. The strongest association is detected in patients with LOMG.

[1]  H. Müller-Hermelink,et al.  Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells. , 2014, Journal of autoimmunity.

[2]  R. Lewis,et al.  Autoantibodies to Agrin in Myasthenia Gravis Patients , 2014, PloS one.

[3]  F. Deymeer,et al.  Association of HLA-DRB1∗14, -DRB1∗16 and -DQB1∗05 with MuSK-myasthenia gravis in patients from Turkey. , 2013, Human immunology.

[4]  M. Battaglia,et al.  Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity. , 2013, Clinical immunology.

[5]  Soumya Raychaudhuri,et al.  Risk for myasthenia gravis maps to a 151Pro→Ala change in TNIP1 and to human leukocyte antigen‐B*08 , 2012, Annals of neurology.

[6]  B. Lie,et al.  Late Onset Myasthenia Gravis Is Associated with HLA DRB1*15:01 in the Norwegian Population , 2012, PloS one.

[7]  R. Lewis,et al.  Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. , 2012, Archives of neurology.

[8]  B. Schoser,et al.  Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis , 2012, Journal of Neurology.

[9]  A. Mussi,et al.  PTPN22 and myasthenia gravis: Replication in an Italian population and meta-analysis of literature data , 2012, Neuromuscular Disorders.

[10]  E. Karataylı,et al.  Association of the PTPN22 gene polymorphism with autoantibody positivity in Turkish rheumatoid arthritis patients. , 2011, Tissue antigens.

[11]  Y. Yamanashi,et al.  Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis , 2011, Annals of neurology.

[12]  H. Müller-Hermelink,et al.  The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis , 2009, Genes and Immunity.

[13]  K. Berger,et al.  The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis. , 2009, Human immunology.

[14]  R. Mägi,et al.  Genetic Structure of Europeans: A View from the North–East , 2009, PloS one.

[15]  D. Sanders,et al.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity , 2009, The Lancet Neurology.

[16]  N. Inanç,et al.  No association of PTPN22 gene polymorphism with rheumatoid arthritis in Turkey , 2009, Rheumatology International.

[17]  M. Marino,et al.  HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5 , 2009, Neurology.

[18]  Yaofeng Zhao,et al.  PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis , 2008, Journal of Neuroimmunology.

[19]  S. Akar,et al.  PTPN22 gene polymorphism in Takayasu's arteritis. , 2008, Rheumatology.

[20]  J. Chang-Claude,et al.  Comparison of the power of haplotype-based versus single- and multilocus association methods for gene × environment (gene × sex) interactions and application to gene × smoking and gene × sex interactions in rheumatoid arthritis , 2007, BMC proceedings.

[21]  A. Rosenwald,et al.  Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS‐1) , 2007, The Journal of pathology.

[22]  S. Ikeda,et al.  Comparison of the histological and immunohistochemical features of the thymus in young- and elderly-onset myasthenia gravis without thymoma , 2007, Journal of Clinical Neuroscience.

[23]  N. Bottini,et al.  Protein tyrosine phosphatase PTPN22 in human autoimmunity , 2007, Autoimmunity.

[24]  M. Pierer,et al.  Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients , 2006, Arthritis research & therapy.

[25]  J. Jais,et al.  Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis , 2006, Annals of neurology.

[26]  R. Yamada,et al.  Ethnic differences in allele frequency of autoimmune-disease-associated SNPs , 2005, Journal of Human Genetics.

[27]  N. Gilhus,et al.  Myasthenia Gravis in Individuals over 40 , 2003, Annals of the New York Academy of Sciences.

[28]  N. Gilhus,et al.  Thymectomy and Antimuscle Antibodies in Nonthymomatous Myasthenia Gravis , 2003, Annals of the New York Academy of Sciences.

[29]  A. Vincent,et al.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies , 2001, Nature Medicine.

[30]  R. Pirskanen,et al.  Polymorphisms at −174 and in the 3′ flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis , 1999, Journal of Neuroimmunology.

[31]  M. Bunce,et al.  A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C. , 1999, Human immunology.

[32]  W. Trojaborg,et al.  EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis , 1999, European journal of neurology.

[33]  R. Vaughan,et al.  HLA-DR and -DQ associations with multiple sclerosis in Turkey. , 1997, Human immunology.

[34]  F. Muntoni,et al.  Sardinian multiple sclerosis is associated with HLA‐DR4 , 1988, Neurology.

[35]  A. Vincent,et al.  Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[36]  A. Vincent,et al.  Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. , 1980, Brain : a journal of neurology.

[37]  J. Lindstrom,et al.  Antibody to acetylcholine receptor in myasthenia gravis , 1976, Neurology.

[38]  Y H Lee,et al.  The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis. , 2007, Rheumatology.

[39]  Nunzio Bottini,et al.  Protein tyrosine phosphatases and the immune response , 2005, Nature Reviews Immunology.